Nymox Reports 2008 Financial Results

HASBROUCK HEIGHTS, N.J., March 13, 2009 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NasdaqCM:NYMX - News) announced today its financial results for the year ended December 31, 2008. Nymox reported a net loss of $4,590,345, or $0.15 per share for the year ended December 31, 2008, compared to $5,290,431, or $0.18 per share for the same period in 2007. The decrease in net losses is attributable to a reduction in expenditures relating to clinical trials in the period. The net loss in 2008 includes Stock Based Compensation charges of $925,220 and amortization and write-down of costs totaling $808,581. Product sales amounted to $426,675 for the year ended December 31, 2008, compared to $412,923 for the same period in 2007. The weighted average number of common shares at the year ended December 31, 2008 was 29,749,000, compared to 29,005,342 at December 31, 2007.

Nymox Pharmaceutical Corporation is a biotechnology company engaged in the research and development of therapeutics and diagnostics, with a particular emphasis on products targeted for the unmet needs of the aging population. The Company's new drug for benign prostatic hyperplasia (BPH) is in Phase 3 development. Currently, Nymox has three products on the market and a healthy pipeline of drug and diagnostic products. The Company also has several hundred patents and patent applications. Nymox has a number of drugs in development for other indications such as E. coli infection, Alzheimer's disease, oncology, and infectious disease. The Company offers NicAlert(tm) and TobacAlert(tm) tests for measuring tobacco product exposure, and AlzheimAlert(tm), a test to aid in the diagnosis of Alzheimer's disease.

More information about Nymox is available at http://www.nymox.com, email: info@nymox.com, or 800-936-9669.

This press release contains certain ``forward-looking statements'' as defined in the United States Private Securities Litigation Reform Act of 1995 that involve a number of risks and uncertainties. There can be no assurance that such statements will prove to be accurate and the actual results and future events could differ materially from management's current expectations. Such factors are detailed from time to time in Nymox's filings with the United States Securities and Exchange Commission and other regulatory authorities.

          Nymox Pharmaceutical Corporation
          Roy Wolvin
          1-800-93NYMOX
          www.nymox.com